Kornimate/medical-research-clean huggingface dataset:
a retrospective review of early onset spinal deformity patients treated with the ellipse magec system

Conditions: Thoracic Insufficiency Syndrome

Summary: the purpose of this study is to determine the safety profile and probable benefit of the ellipse technologies inc. magec system in subjects with early onset spinal deformity associated with thoracic insufficiency syndrome.


Eligibility criteria:
inclusion criteria: * early onset spinal deformity with any etiology * cobb angle measurement of 30 degrees or greater at the time of primary surgery * thoracic spine height (t1 to t12) less than 22 cm at the time of primary surgery * age less than 11 years old at the time of magec implant * implanted with the magec system as either a primary or secondary revision spinal bracing procedure * patient has been implanted for a minimum of 6 months * patient signs informed consent for the use of their personal private data exclusion criteria: * patient declines to sign informed consent for the use of their personal private data.

Keywords: thoracic insufficiency syndrome early onset spinal deformity
one week of magnesium supplementation lowers il-6, perceived pain and increases post exercise blood glucose in response to downhill running

Conditions: Magnesium Deficiency

Summary: this study investigated the effect of magnesium supplementation on exercise performance and functional recovery in recreational endurance athletes in conjunction with measures of blood glucose, lactate, il-6 and sil-6r.

magnesium status can directly affect circulating glucose concentrations both during and post exercise. in addition, magnesium supplementation has been shown to reduce circulating il-6 concentrations post exercise in humans. it is conceivable that such observations are linked through the role of il-6 in glucose regulation, possibly in combination with sil-6r. together, magnesium intake may have the potential to effect exercise performance and recovery through glucose availability. this in turn may be connected to the production of il-6 and sil-6r which have been established to influence exercise fatigue and perception of pain (muscle soreness).

Eligibility criteria:
inclusion criteria: * regular recreational runner, running around 3 times per week * capable of running 10 km in \~ 40 minutes. exclusion criteria: * any signs or symptoms of cardiovascular issues. * any recent form of injury or illness. * currently, or in the last 3 months, have consumed multivitamin supplements * currently, or in the last 3 months, have consumed anti-inflammatory medications.

Keywords: magnesium supplementation interleukin-6 soluble interleukin-6 receptor glucose pain exercise performance exercise recovery downhill running
post-covid condition cohort: evolution of symptomatology, patient profile and associated prognostic factors

Conditions: Long COVID; Post-Acute COVID-19; Post-Acute COVID19 Syndrome

Summary: the aim of our cohort is to collect prospectively, in a standardized and exhaustive manner, the health data of patients referred to the capcov, our holistic referal post covid clinics for post-covid condition in order to be able to identify typical profiles of patients suffering from post covid syndrome and to follow the evolution of their disease over time.


Eligibility criteria:
inclusion criteria: * outpatients treated in the nancy university hospital long covid support and care center for post-covid condition according to who definition exclusion criteria: * patient opposing the processing for research purposes of their data collected in routine care for their care
real-time cholangioscopy artificial intelligence evaluation of biliary strictures

Conditions: Biliary Stricture

Summary: the purpose of this study is to demonstrate the feasibility and validity of a previously developed peroral cholangioscopy (poc) convolutional neural network (cnn) to determine the etiology of biliary strictures when used in real-time.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * anticipation that patient may undergo poc during an endoscopic retrograde cholangioscopy * pregnant patients can be included in the study. use of the poc-cnn does not convey any new risk to the patient nor fetus. * non-english speaking subjects will be included in the study. consent for the procedure itself is always done with the assistance of an interpreter via telephone or video. use of the poc-cnn will be discussed with all patients via this interpreter during the procedure consent. exclusion criteria: * age \<18 years old * no indication that cholangioscopy will be performed during endoscopic retrograde cholangiopancreatography (ercp) * prisoner
maternal postop temperature after cesarean delivery

Conditions: Temperature Change, Body; Cesarean Delivery; Spinal Anesthesia

Summary: it is unclear whether routine addition of intra-operative forced-air warming in addition to warmed intravenous fluids during cesarean delivery under spinal anesthesia is beneficial. in this single-center randomized trial, we aim to test the primary null hypothesis that our current protocol of warmed intravenous fluids is similar to a combination of warmed intravenous fluids with intra-operative lower-body forced-air warming to maintain maternal temperature after cesarean delivery under spinal anesthesia. we also aim to assess the rate of maternal shivering during and after the procedure between the two groups, the maternal thermal comfort score, neonatal apgar scores and umbilical ph levels. if we demonstrate no clinically important difference between the two interventions, clinicians will be able to continue our current protocol of warmed intravenous fluids only during cesarean delivery.

primary aim investigate whether a combination of intra-operative lower-body forced-air warming and warmed iv fluids is superior to our current standard of warmed iv fluids alone in influencing maternal core temperature following spinal anesthesia for cesarean delivery. secondary aim 1. to compare mean core temperature on arrival to post-anesthesia care unit (pacu) in women who received combination of intra-operative lower-body forced-air warming and warmed iv fluids versus iv fluids alone 2. to compare incidence of hypothermia among women who received combination of intra-operative lower-body forced-air warming and warmed iv fluids versus iv fluids alone 3. to compare incidence of shivering following recovery in post anesthesia care unit (pacu) in women who received combination of intra-operative lower-body forced-air warming and warmed iv fluids versus iv fluids alone 4. to compare thermal comfort levels for women who received combination of intra-operative lower-body forced-air warming and warmed iv fluids versus iv fluids alone 5. to compare use of meperidine in post anesthesia care unit (pacu) to treat postoperative shivering, in women who received combination of intra-operative lower-body forced-air warming and warmed iv fluids versus iv fluids alone 6. to compare newborn outcomes (rectal temperature at birth, umbilical vein ph \& apgar scores post-delivery) in women who received combination of intra-operative lower-body forced-air warming and warmed iv fluids versus iv fluids alone

Eligibility criteria:
inclusion criteria: 1. written informed consent 2. age between 18-50 years old 3. american society of anesthesiologists (asa) physical status 2-3 4. gestational age greater than 37 completed weeks 5. singleton pregnancy 6. elective cesarean delivery. exclusion criteria: 1. known allergy to local anesthetics 2. contraindication for spinal anesthesia 1. patient refusal 2. bleeding diathesis 3. neuropathy
non-invasive cerenkov luminescence imaging of lymphoma, leukemia and metastatic lymph nodes

Conditions: Head and Neck Cancers

Summary: the purpose of this study is to see if a new way of imaging called the cerenkov luminescence or effect that is used with a standard clinical pet/ct and/or investigation scans can be done in order to capture tumor sizes. the investigators believe endoscopies and surgical procedures could benefit from this type of imaging in the future. the cerenkov imaging could be used as a guide for surgical resections. the purpose of this study is to use the cerenkov light from fdg, iodine-131 tracer sand/or other investigational tracers to image tumors and its sizes in the head, neck, breast, axillary and pelvic regions with a highly sensitive camera. the investigators will be trying to see if we can get another picture of the tumor using the cerenkov light as part of the standard clinical scan or therapy.


Eligibility criteria:
inclusion criteria: * participant is 18 years of age or older. * participant is scheduled for standard clinical and/or investigational pet/ct scan or 131i therapy within the nuclear medicine service at main hospital. * patients must have had pathologic lymph node metastases in the neck, axillary or inguinal area (do not need to be biopsy proven) from either leukemias, lymphomas: , head and neck cancers (e.g. tonsillar, nasopharynx, tongue carcinoma, breast cancer or melanoma;or lymphoma or tonsillar or squamous cell carcinoma with metastases in the neck region for pet/ct imaging, or thyroid cancer for thyroid ablation therapy. any other more infrequent cancer metastasizing with nodal metastasis in the neck, axilla and inguinal regions to cervical lymph nodes is eligible as well as the primary goal is to image pathological (i.e. hypermetabolic) lymph nodes. * patients with hypermetabolic activity and uptake in the neck,axilla, breast and inguinal region on scan, defined visually as significant lesion suspicious for malignancy by a nuclear medicine physician or trainee. (we will include a subset of patients with normal lymph nodes during screening. this subset of patients will be imaged as a negative control for this study.) exclusion criteria: * patients imaged for cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition, potentially covered by a dark cloth in case that the ambient light level remains too high for the ultra-sensitive camera. any conditions that would prevent this will exclude the patients. * there are any other past medical, physiological or demographic concerns. this includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique.

Keywords: 18f-fdg pet/ct scan 131i therapy cerenkov luminescence imaging 12-050 lymphoma leukemia metastatic lymph nodes
plasma p-tau2017 and quantitative amyloid pet imaging

Conditions: Alzheimer Disease

Summary: the overall goal of this protocol is to compare amyloid burden assessed by amyloid pet to plasma p-tau217 levels.

the overall goal of this protocol is to compare amyloid burden assessed by amyloid pet to plasma p-tau217 levels. other relevant ad-related investigational biomarkers may also be assessed in the provided samples. apolipoprotein e (apoe) genetic status will be evaluated with a serum sample.

Eligibility criteria:
inclusion criteria (for all participants): * signed and dated written informed consent obtained from the subject. * male participants with partners of childbearing potential must commit to the use of 2 methods of contraception, one of which is a barrier method for male participants for the study duration. * male participants must not donate sperm for the study duration. * willing and able to cooperate with study procedures. * males and females. * participants aged ≥ 70, inclusive, at the time of screening. * judged to be cognitively normal by an investigator based on clinical judgment. exclusion criteria (for all participants): * subject has received an investigational drug or device within 30 days of enrollment, unless in the opinion of the investigator such medication or device will not impair subject safety or scientific integrity of the data. * contraindication to amyloid pet imaging or blood sampling. * have ever received an experimental or approved medication targeting amyloid or tau. * prior participation in other research protocols or clinical care in the last year that would result in radiation exposure exceeding the acceptable annual limit established by the u.s. federal guidelines (effective dose of 50 msv, including the procedures in this clinical protocol). * pregnancy, lactating or breastfeeding. * evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, alternative neurological, immunodeficiency, pulmonary, or other disorder or disease that in the investigator's judgment may interfere with the objectives of the study. * unsuitable veins for venipuncture.

Keywords: ad
role of endothelin-a (eta) and endothelin-b (etb) receptors in the vasodilatory response to endothelin-3 (et-3)

Conditions: Pulmonary Arterial Hypertension; Vasodilation; Vasoconstriction

Summary: endothelin-1 (et-1) has been linked to a number of conditions including pulmonary arterial hypertension (pah). et-1 acts via 2 receptors, eta and etb. the et-1 receptor blockers bosentan and sitaxsentan have been shown to be beneficial in patients with pah. bosentan blocks both eta and etb receptors. sitaxsentan selectively blocks eta receptors. theoretically, selective eta blockade may be associated with greater vasodilation and clearance of et-1 by leaving the etb receptor unblocked. this has not been directly studied in humans. we aim to investigate the endothelial etb-mediated vascular responses between bosentan and sitaxsentan by using a etb selective agonist (et-3). we hypothesise that at clinically relevant doses: * bosentan will show evidence of etb receptor blockade compared to sitaxsentan and placebo. * these effects will be confirmed by 2 functional markers of etb receptor antagonism: plasma et-1 (a very sensitive, but not necessarily clinically relevant marker), and the forearm vasodilator response to et-3.


Eligibility criteria:
inclusion criteria: * healthy men and post-menopausal women * age 18-70 years * bmi 18-35 kg/m2 exclusion criteria: * are mentally or legally incapacitated * have donated blood within the last 4 weeks * have a history of past or present drug or alcohol abuse * have participated in another clinical trial within 1 month * are considered to be at a high risk of hiv or hepatitis b * are taking routine medicines * are women taking hormone replacement therapy * have significant medical or psychiatric illness

Keywords: forearm blood flow vasodilation vasoconstriction endothelin system endothelin-1 endothelin-3 endothelin antagonists bosentan sitaxsentan endothelin regional blood flow
effect of bazedoxifene, raloxifene, and placebo on breast density

Conditions: Breast Cancer

Summary: it has been shown that women who have dense breasts have an increased risk of breast cancer compared with women whose breasts are less dense. however, while breast density may be a risk factor, the etiology of the relationship between breast cancer and breast density is not understood. furthermore, it is well recognized that breast cancer can still develop in women whose breasts are not dense. at menopause, the amount of breast glandular tissue and stroma naturally decreases due to a lack of hormonal stimulation. this is characterized as a decrease in the mammographic density. although certain medications, including hormone therapy (ht) and dopamine antagonists can increase breast density, these effects are reversible upon discontinuation of the specific agent. other medications such as the selective estrogen receptor modulators (serm), raloxifene (ral) and tamoxifen, have been shown to not affect breast density and allow the normal age-related changes to occur. the effects of bazedoxifene (bza), a new serm, on breast density are not known. the purpose of this study is to examine the effect of bza on breast density changes over 24 months in postmenopausal women. the results may be useful for clinicians to understand the effect of bza on breast density and its mammographic effects. this is an observational, multicenter, double-blind, randomized, placebo- and active comparator-controlled study. it is also an ancillary that will use women who are already participants in a phase 3 trial for fracture reduction (protocol 3068a1-301-ww; primary study). in the primary study, subjects received bza 20 mg, bza 40 mg, ral 60 mg, or placebo. this ancillary study will request a subset of participants to use their mammograms taken in this study. their mammogram will be digitized by a central imaging center. a single radiologist will perform the quantifications of breast density from the digitized mammograms.


Eligibility criteria:
1. each subject must have participated or is currently participating in study 3068a1 301, and must satisfy all of the following criteria 2. has completed 24 months of treatment. 3. had a mammogram at the baseline visit and at the month 24 visit, and both are original films that are technically acceptable for reading. 4. was less than or equal to 62 years of age at the time of study randomization in the primary study. 5. was at least 80% compliant with test article administration. 6. did not take any medications 6 months prior to screening in the primary study or during the first 24 months of the study that could cause a change in breast density. 7. was enrolled at a site that has at least 4 subjects meeting all of the above inclusion criteria. 8. was enrolled at a clinical site that is still participating in the primary study.
acute effect of lemborexant on csf amyloid-beta and tau

Conditions: Alzheimer Disease

Summary: this study will look at the effects of lemborexant on alzheimer's disease biomarkers found in the cerebrospinal fluid (csf) and blood in individuals who are poor sleepers

this study will determine the acute effect of lemborexant on cns tau phosphorylation and other alzheimer's disease biomarkers in individuals with poor sleep quality.

Eligibility criteria:
inclusion criteria: * age 60-80 years * any sex * any race/ethnicity * mini-mental status examination score (mmse) ≥ 27 * positive plasma amyloid-beta test (i.e., amyloid-positive) * pittsburgh sleep quality index \>5 exclusion criteria: * cognitive impairment as determined by history of mmse \< 27 * inability to speak or understand english * any sleep disorders other than insomnia * no history of moderate-to-severe sleep-disordered breathing and stop-bang score \> 5 * history or reported symptoms suggestive of restless legs syndrome, narcolepsy or other sleep disorders * no more than mild sleep apnea (ahi \<16) on psg * sleep schedule outside the range of bedtime 22:00-midnight * contraindication to lumbar catheter (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery) * cardiovascular disease requiring medication except for controlled hypertension (pi discretion) * stroke * hepatic or renal impairment * pulmonary disease (pi discretion) * type 1 diabetes * hiv or aids * neurologic or psychiatric disorder requiring medication (pi discretion) * suicidal ideations * alcohol, tobacco or marijuana use (pi discretion) * use of sedating medications (pi discretion) * inability to get out of bed independently * in the opinion of the investigator, the participant should be excluded due to an abnormal physical examination. * current pregnancy * body mass index \>35 * history of migraines (pi discretion) * history of drug abuse in the last 6 months * history or presence of any clinically significant medical condition, behavioral or psychiatric disorder (including suicidal ideation), or surgical history based on medical record or patient report that could affect the safety of the subject or interfere with study assessments or in the judgment of the pi participant is not a good candidate. * urinary or fecal incontinence * concurrently enrolled in another trial of an investigational drug or device

Keywords: poor sleep
case management and environmental control in asthma

Conditions: Asthma

Summary: asthma among low-income, minority children remains a prime example of health disparities that are resistant to change. controlled demonstrations of reductions in disproportionate hospital or emergency care are limited. we performed a controlled clinical trial of an "asthma coach" to reduce hospitalizations among low-income, african american children.


Eligibility criteria:
inclusion criteria: * 2-8 years of age * admitted to hospital for acute asthma * african american ethnicity * medicaid coverage exclusion criteria: * parent refusal to sign consent * living outside service area

Keywords: asthma children low-income, underserved reduction in hospitalization
remotely delivered resistance training for cardiometabolic health among black women

Conditions: Overweight or Obesity; Prediabetes or Diabetes; Prehypertension (Elevated Blood Pressure) or Hypertension; Resistance Training

Summary: the purpose of this study is to collect preliminary data on the feasibility, acceptability, and potential effects of a novel, remotely delivered resistance training program.

this trial will enroll black women with elevated cardiometabolic risk (e.g., overweight or obesity, pre- or established diabetes, and elevated or high blood pressure) in early-to-middle adulthood (n=36; age=30-64 years) with insufficient resistance training (rt) participation. this 4-month single group pilot trial evaluates the feasibility, acceptability, and potential effects of a novel, remotely-delivered resistance training (rt) intervention. all participants will engage in rt during this trial and the web-based platform is the primary modality through which the remote rt intervention is delivered. assessments are conducted at baseline and follow-up (month 4). aim 1 will examine the feasibility and acceptability of the remotely delivered rt program. aim 2 will examine the potential effects on rt behaviors. aim 3 will examine the potential effects on clinical and patient-reported outcomes.

Eligibility criteria:
inclusion criteria: * self-identifies as black or african american * female * age 30-64 years * insufficient resistance training engagement (\<2 sessions/week in the past 6 months) and * self-reported or documented diagnosis of at least one of the following conditions: overweight, obesity, prediabetes, type 2 diabetes, elevated blood pressure, hypertension, or taking medications for any of these conditions * has an internet- connected device (i.e., computer, smartphone) and is willing to use it for intervention delivery * if indicated during screening, willing to obtain medical clearance for exercise from their healthcare provider prior to enrollment * residing within a 50-mile radius of the university exclusion criteria: * uncontrolled hypertension (blood pressure \>160/100 mm hg) * weighing ≥ 450 lbs (upper limit for body composition assessment) * conditions or limitations that affect physical activity participation and/or the ability to --perform assessments * has a medical or physical condition that make moderate intensity physical activity (like a brisk walk) difficult or unsafe * unwilling to obtain medical clearance (if indicated by prescreening) * women who are pregnant or trying to become pregnant in the next 6 months * planning to relocate out of the area in the next 6 months * participating in another exercise and/or randomized research project * unwilling or unable to do any of the following: give informed consent; read/understand english; perform resistance training in their home, record and upload virtual exercise assessment sessions, and other protocol specific requirements